Literature DB >> 12649106

Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy.

F Panzuto1, M Falconi, S Nasoni, S Angeletti, A Moretti, M Bezzi, G Gualdi, E Polettini, R Sciuto, A Festa, F Scopinaro, V D Corleto, C Bordi, P Pederzoli, G Delle Fave.   

Abstract

BACKGROUND: In patients with digestive endocrine tumours, complete pre-operative staging is essential in planning proper management and evaluating treatment efficacy. To date, somatostatin receptor scintigraphy (SRS) is considered the 'gold standard' imaging procedure, and very few data are available concerning the use of helical computed tomography (hCT). This study aimed to determine the diagnostic accuracy and the ability to modify the surgical management of hCT, alone or combined with SRS. PATIENTS AND METHODS: Sixty patients were staged before surgery by hCT, SRS and tumour markers, and included in group 1 if suitable for radical surgery, otherwise in group 2. All patients underwent laparotomy followed by subsequent re-staging.
RESULTS: SRS sensitivity was 77%, 48% and 67% for primary, lymph-node and liver lesions, respectively. hCT sensitivity was 94%, 69% and 94% for primary, lymph-node and liver lesions, respectively (P = 0.02 versus SRS, for liver lesions). During pre-operative evaluation, hCT correctly staged 92% and SRS 75% of patients (P = 0.02). hCT provided additional information in 17% of patients.
CONCLUSIONS: Since hCT has been shown to be extremely accurate, providing essential information for the planning of surgical treatment compared with that of SRS, both techniques should be used in the pre-operative work-up of digestive endocrine tumours.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649106     DOI: 10.1093/annonc/mdg160

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

1.  Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades.

Authors:  Feng Jin; Kai Wang; Ting-Ting Qin; Xin Li; Feng Guo; Gui-Na Ma; Xue-Han Hu; Ping Han
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

Review 2.  Molecular imaging of neuroendocrine tumors.

Authors:  Jorge A Carrasquillo; Clara C Chen
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 3.  Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.

Authors:  Jeffrey A Norton; Robert T Jensen
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

Review 4.  Multimodal management of neuroendocrine liver metastases.

Authors:  Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

5.  Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.

Authors:  F Panzuto; C Severi; R Cannizzaro; M Falconi; S Angeletti; A Pasquali; V D Corleto; B Annibale; A Buonadonna; P Pederzoli; G Delle Fave
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

6.  Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy.

Authors:  Liesbeth M Veenendaal; Inne H M Borel Rinkes; Cornelis J M Lips; Richard van Hillegersberg
Journal:  World J Surg Oncol       Date:  2006-06-26       Impact factor: 2.754

Review 7.  Hepatic arterial embolization in patients with neuroendocrine tumors.

Authors:  Michela Del Prete; Francesco Fiore; Roberta Modica; Vincenzo Marotta; Francesca Marciello; Valeria Ramundo; Antonella Di Sarno; Annachiara Carratù; Chiara de Luca di Roseto; Salvatore Tafuto; Fabiana Tatangelo; Robero Baldelli; Annamaria Colao; Antongiulio Faggiano
Journal:  J Exp Clin Cancer Res       Date:  2014-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.